Drugs in MeSH Category Trypanocidal Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	PENTAMIDINE ISETHIONATE	pentamidine isethionate	INJECTABLE;INJECTION	206982-001	Mar 17, 2022		DISCN	No	No
Uswm	IWILFIN	eflornithine hydrochloride	TABLET;ORAL	215500-001	Dec 13, 2023		RX	Yes	Yes
Pai Holdings	PENTAMIDINE ISETHIONATE	pentamidine isethionate	FOR SOLUTION;INHALATION	206667-001	Apr 24, 2019	AN	RX	No	No
Fresenius Kabi Usa	NEBUPENT	pentamidine isethionate	FOR SOLUTION;INHALATION	019887-002	Mar 22, 1996		DISCN	No	No
Fresenius Kabi Usa	PENTAM	pentamidine isethionate	INJECTABLE;INJECTION	019264-001	Oct 16, 1984	AP	RX	Yes	Yes
Avet Lifesciences	PENTAMIDINE ISETHIONATE	pentamidine isethionate	INJECTABLE;INJECTION	213806-001	Jan 7, 2021	AP	RX	No	No

Last updated: July 25, 2026

Market dynamics and patent landscape for Trypanocidal Agents (MeSH: Trypanocidal Agents)

Executive summary: Trypanocidal Agents (MeSH) span a narrow set of actives used for African trypanosomiasis (HAT), Chagas disease (American trypanosomiasis), and related kinetoplastid infections. The patent estate is dominated by originator small-molecule IP (notably nifurtimox, benznidazole, melarsoprol, eflornithine, nifurtimox derivatives, and dose/formulation-specific follow-on patents) with limited remaining exclusivity in most geographies. Current market dynamics are shaped by: (1) procurement programs and treatment guidelines, (2) generics and authorized suppliers for legacy therapies, (3) the pace of clinical development for next-generation oral and combination regimens (including stage-discovery-to-phase-transition risk), and (4) regulatory and IP friction around formulation and method-of-use claims. The near-term IP risk for new entrants concentrates in US Orange Book and FDA labeling carve-outs for method-of-use and dosage-form IP, while exclusivity outcomes for new chemical entities depend on patent term extension and pediatric exclusivity.

---

Which drugs are included in MeSH “Trypanocidal Agents” and how are they used commercially?

Answer: MeSH “Trypanocidal Agents” broadly covers therapeutics active against Trypanosoma and related kinetoplastids, including HAT and Chagas disease regimens. Commercial utilization is driven by national control programs and donor procurement for HAT, and endemic-country public health programs for Chagas disease, with smaller pull from private care in non-endemic regions.

Key actives and typical indications

HAT (African trypanosomiasis, Trypanosoma brucei)

• Melarsoprol (older arsenical; limited modern use due to toxicity and regimen preferences)
• Eflornithine (for late-stage disease, where used)
• Nifurtimox is primarily for Chagas, but appears in historical kinetoplastid therapy coverage
• Newer HAT regimens depend on regional formularies and procurement

Chagas disease (American trypanosomiasis, Trypanosoma cruzi)

• Benznidazole (core therapy; long-established)
• Nifurtimox (alternative/adjunct therapy)

Other kinetoplastid/tryponocide-adjacent actives (coverage varies by MeSH mapping)

• Public-health use patterns and marketing authorization differ by country

Commercial structure

• Public-sector dominated demand: For HAT and Chagas, sales are typically linked to tenders, disease-control programs, and donor-funded procurement rather than broad retail markets.
• Price competition: Legacy small molecules face generic availability and tender-driven price compression.
• Pipeline effect is uneven: Even where clinical progress occurs for next-gen candidates, adoption is bounded by local regulatory approvals and guideline changes.

---

What does the current patent estate for Trypanocidal Agents look like by active ingredient?

Answer: The tryponocidal IP landscape is mostly a legacy-driven patchwork: primary composition-of-matter patents for classic actives are largely expired or near-expiry, while remaining enforceable value sits in follow-on patents such as formulations, dosing regimens, manufacturing methods, and (in the US) potentially method-of-use claims.

US and EU enforcement patterns

• US: Enforceability often depends on whether the branded product has an Orange Book listing (drug product patents and method-of-use patents) and whether generic challenges target those listed patents via Paragraph IV.
• EU: Enforcement typically relies on national translations and the scope of granted EPs (and the ability to enforce via unitary patents where applicable).
• Common follow-on themes:
  • fixed dosing intervals and regimen definitions for efficacy-toxicity balancing
  • improved formulations (solubility, stability, taste-masking, or pediatric-friendly dosage forms)
  • manufacturing impurities and process controls

Legacy actives with high generics exposure

• Benznidazole and nifurtimox: In most markets, composition-of-matter exclusivity is historical; commercial differentiation is usually constrained to formulation IP or regulatory data exclusivity tied to specific products rather than to actives themselves.

---

When do key Trypanocidal Agents lose exclusivity in the US and how do paragraph IV risks change over time?

Answer: For most legacy tryponocidal actives, exclusivity windows are long past or ending, shifting the generic-entry risk profile from primary patent cliffs to residual method-of-use and formulation patents tied to specific labeled regimens and dosage forms.

How generic risk typically manifests

• Orange Book-driven timing: If drug product or method-of-use patents are listed, generic applicants can attempt Paragraph IV challenges to accelerate approval for the specific strength and dosage form.
• Last-mover advantage for follow-on patents: Where originators still have enforceable follow-on patents, generics may face delayed launches for the patented strength or regimen.
• Settlement structures: Where patent litigation occurs, settlements often trade off shared market exclusivity for an agreed launch date, sometimes with labeling carve-outs.

Practical timing takeaway

• The incremental value of tracking patent cliffs for these actives is mainly tied to:
  • remaining formulation/process patents for specific branded dosage forms
  • US-only method-of-use patents with enforceable claims that overlap with labeling

---

What patents protect benznidazole and nifurtimox regimens, formulations, and manufacturing methods?

Answer: For benznidazole and nifurtimox, the patent estate usually concentrates on formulation and regimen-defined claims, since original composition-of-matter protection is largely expired in major markets.

Where IP value tends to remain

• Oral dosage forms: improvements to tablet strength, excipient systems, dissolution profile, and stability for shelf-life extension.
• Dose regimens: claims around duration and dosing schedule that optimize tolerability and clinical outcomes.
• Manufacturing processes: impurity profiles, polymorph control, and process parameters.

Competitive landscape implications

• Because the actives are mature, differentiation is more likely to appear in:
  • product-specific regulatory dossiers
  • formulation patent fencing (limited scope but can affect launch timing)
  • tender procurement of approved brands

---

Which patents protect HAT therapies like melarsoprol and eflornithine, and what barriers exist for generics?

Answer: For melarsoprol and eflornithine, generic barriers depend on the state of any remaining product/formulation patents and the practical constraints of manufacturing and regulatory approval for high-toxicity injectables.

Key barriers for generic entry

• Sterile injectable complexity: manufacturing controls and batch consistency requirements can delay generic development.
• Regulatory labeling constraints: even where generics are approved, adoption may require guideline and procurement alignment.
• Narrow patent holdouts: where any method-of-use or regimen patents remain, they can impact US labeling and can be targeted in Paragraph IV challenges.

Litigation likelihood

• For mature HAT drugs, litigation is less frequent than for blockbuster oncology or immunology drugs, but can still occur where Orange Book listings and US approval pathways overlap.

---

What is the Orange Book status of Trypanocidal Agents and which listed patents create US generic launch leverage?

Answer: For the MeSH class as a whole, Orange Book leverage is concentrated in any remaining drug product and method-of-use patents still listed for specific branded presentations. The practical question for a generic entrant is not the class but the labeled product: strength, dosage form, route, and method-of-use alignment.

How to interpret Orange Book listings for tryponocidal drugs

• Drug substance vs drug product patents: For many legacy actives, drug substance patents are stale or expired. Drug product patents (formulation, polymorph, manufacturing) and method-of-use patents can be the last remaining levers.
• Generic application strategy: Paragraph IV is typically used only when a listing exists that the applicant can plausibly challenge while maintaining labeling compatibility.

---

What patent litigation affects Trypanocidal Agents and how do settlements typically change launch dates?

Answer: Litigation involving tryponocidal agents tends to be episodic and driven by the presence of actionable Orange Book patents for a specific branded product. When settlements occur, they usually set:

• an agreed-at-risk launch date for a generic strength/dosage form
• labeling carve-outs to avoid direct overlap with method-of-use claims
• market-exclusivity windows tied to final resolution dates

Common settlement patterns

• Launch-date deferral: Generic entry occurs after a fixed date rather than at the earliest possible FDA approval date.
• Narrow labeling: Generics may launch for indications or regimen descriptions that do not infringe method-of-use claims.
• Technology license terms: Less common for mature actives, but can occur where formulation know-how is needed to support comparability.

---

How does the risk profile differ for small-molecule generics versus next-generation tryponocidal candidates?

Answer: Generics of legacy small molecules face IP risk bounded by any remaining formulation/method-of-use patents. Next-generation candidates face a different profile: longer patent runways but higher clinical and regulatory failure risk, plus potential combination-regimen exclusivity and complex method-of-use claim sets.

Two-track risk model

1. Legacy track (benznidazole/nifurtimox and older HAT agents):

   • low clinical risk (already validated)
   • moderate residual IP risk (limited number of last-mile patents)
   • high procurement relevance but price pressure

2. Pipeline track (new chemical entities and combos):

   • high development and trial-risk
   • high patent density possible (composition, salt/polymorph, formulation, dosing, combinations)
   • long exclusivity tail if approved with meaningful differentiation

---

What formulation patents and manufacturing process patents are most likely to block generic competition?

Answer: For tryponocidal agents, the patents most likely to block competition are those tied to:

• dosage form quality attributes (dissolution, stability, bioavailability in label-relevant conditions)
• pediatric and low-dose strength formulation specifics
• sterile manufacturing controls for injectables
• impurity specifications and polymorph control relevant to comparability

Enforceability drivers

• claim scope: whether it maps to generic manufacturing approaches and label
• product-specific listing: whether the patent is listed in Orange Book and thus affects FDA approval timing
• proof burdens: infringement often hinges on manufacturing details and analytical characterization

---

How do next-generation Chagas disease and HAT pipelines affect patent strategy and market timing?

Answer: Pipeline entrants shift market timing by changing guideline adoption and procurement priorities. Patent strategy also shifts toward:

• combination regimens (fixed-dose or regimen-defined)
• method-of-use claims capturing treatment stages and patient subsets
• pediatric dosing and formulation differentiation

Business impact

• Procurement lock-in: Once procurement contracts and guidelines favor a new regimen, legacy sales can decline despite persistent generic IP opportunities.
• IP stacking: New entrants may build thicker estates by layering drug product and method-of-use patents across multiple formulations and dosing schedules.

---

How does Trypanocidal Agents MeSH compare with adjacent antiparasitic MeSH classes on IP density and generic penetration?

Answer: Compared with many other antiparasitic MeSH classes, Trypanocidal Agents show:

• high generic penetration for legacy actives
• lower historical blockbuster-like patent density at the active-substance level
• more practical value in formulation, dosage regimen, and regulatory product differentiation

Implications

• For licensing or investment, the most investable IP moments are often:
  • late-stage formulation differentiation
  • regulatory-proximal exclusivity (depending on jurisdiction)
  • combination-regimen IP that changes standard-of-care

---

Geographic exposure: where are generics most likely to enter and where is branded protection most persistent?

Answer: Generic penetration is highest where:

• legacy actives are widely approved and tendered
• manufacturing requirements are less restrictive
• labeling does not include tight method-of-use constraints tied to Orange Book patents

Branded protection tends to persist longer where:

• there are still actionable formulation/method-of-use patents for specific labeled presentations
• public-sector procurement continues to favor branded procurement channels
• regulatory and guideline adoption cycles lag after generic entry

---

Key Takeaways

• Trypanocidal Agents are dominated by mature small molecules; the enforceable patent value typically sits in follow-on formulation and regimen claims rather than in active-substance composition.
• US generic launch leverage is determined by Orange Book-listed drug product and method-of-use patents tied to specific strengths and dosage forms.
• Litigation is episodic and depends on whether actionable Orange Book listings exist; when settlements occur, they commonly set fixed launch dates or labeling carve-outs.
• Pipeline candidates can reshape market dynamics quickly via guideline and procurement adoption, with thicker patent estates expected around combinations and dosing regimens.
• The highest near-term entry risk for generics is concentrated in last-mile formulation/manufacturing and method-of-use IP that maps to labeled regimens.

---

FAQs

1. What types of patents most often remain enforceable for benznidazole and nifurtimox after composition-of-matter expiry?
2. How do Paragraph IV challenges in the US typically target tryponocidal products when method-of-use patents are listed?
3. What labeling elements for HAT injectables most affect whether a generic can launch without infringement?
4. How do procurement and guideline adoption cycles in endemic countries change the economic payoff of new tryponocidal regimens?
5. What patent stacking strategies do next-generation Chagas disease candidates commonly use to extend exclusivity beyond initial approval?

---

References (APA)

1. U.S. National Library of Medicine. (n.d.). MeSH: Trypanocidal Agents. National Institutes of Health. https://www.ncbi.nlm.nih.gov/mesh/
2. U.S. Food and Drug Administration. (n.d.). Drug Trials Snapshots and FDA drug approval and labeling resources. https://www.fda.gov/